Research Notes

Stay informed with the most recent market and company research insights.

A man sitting at a table with a glass of orange juice.

Research Notes

International Spotlight

Visa Inc. Class A
3:27pm
June 5, 2025
VISA is a global payments technology company that enables fast, secure and reliable electronic payments across more than 200 countries and territories. It facilitates global commerce through the transfer of value and information among a global network of consumers, merchants, financial institutions, businesses, strategic partners, and government entities

The GOAT of OAT

SomnoMed
3:27pm
June 5, 2025
SOM is the world’s largest OEM of oral appliance therapies (OAT) that treat mild to moderate obstructive sleep apnoea (OSA). OSA is caused by throat muscles relaxing while you sleep and narrowing or obstructing the airways causing breathing pauses or shallow breathing, resulting in reduced oxygen levels (hypoxia) and disrupted sleep. SOM’s devices advance the jaw and tongue which in turn pull the throat muscles forward and provide clearance for more air to pass through, reducing hypoxic events. SOM has experienced significant changes over the last 18 months, noting a swing to profitability through improved sales, manufacturing capacity increases, cost-base restructure, and repayment of debt facilities.

International Spotlight

Novo Nordisk A/S
3:27pm
June 5, 2025
Novo Nordisk is a Danish multinational pharmaceutical company providing innovative treatment for five chronic diseases. Its products treat type 1 and 2 diabetes, obesity, haemophilia and growth disorders. It is most known for its diabetes treatments. Ozempic is its main revenue stream, which is for the treatment of adults with insufficiently controlled type 2 diabetes.

International Spotlight

Mastercard Inc
3:27pm
June 5, 2025
Mastercard is a technology company that provides transaction processing and other payment-related products and services in the United States and internationally. It facilitates the processing of payment transactions, including authorisation, clearing, and settlements. The company offers integrated products and value-added services for account holders, merchants, financial institutions, businesses, governments, and other organisations.

International Spotlight

Eli Lilly
3:27pm
June 4, 2025
Eli Lilly and Co is an American pharmaceutical company headquartered in Indianapolis. It engages in the discovery, development, manufacture and sale of pharmaceutical products. Its portfolio of medicine includes treatments in the areas of bone muscle joints, cancer, cardiovascular, diabetes, endocrine, immunology, neurodegeneration, neuroscience, and pain. Its products include Forteo, Adrica, BAQSIMI, Basaglar and Glucagn.

International Spotlight

AstraZeneca PLC
3:27pm
June 4, 2025
AstraZeneca is an Anglo-Swedish multinational pharmaceutical and biotechnology company headquartered in Cambridge, England. It is science-led and patient-focussed within its four primary therapy areas: Oncology, Biopharmaceuticals, Vaccine and Immune Therapies; and Rare Diseases. AstraZeneca is focussed on the discovery, delivery and commercialisation of prescription medicines.

IP Generation acquisition

MA Financial Group
3:27pm
June 4, 2025
MAF has acquired IP Generation, a real estate investment management firm specialising in Australian shopping centres. In our view, the IP generation deal is a nice bolt-on for MAF with the deal being slightly EPS accretive (pre-synergies), and adding greater scale and capability to MAF’s Asset Management platform. We make nominal changes to our MAF FY25F EPS, but lift FY26F EPS by 2% on the IP Generation acquisition (and some minor tinkering to our other earnings assumptions). Our target price rises to A$8.23 (from A$8.11). We believe MAF management is building a strong, differentiated client franchise. We have an ACCUMULATE recommendation, with ~18% TSR existing.

A long-anticipated merger

WH Soul Pattinson & Co
3:27pm
June 4, 2025
SOL has announced it has entered into a binding agreement with BKW to unwind the cross-shareholding that has existed between the two entities since 1969 and merge. Concurrently, an equity raise would be undertaken to facilitate transaction costs, cover BKW debt and SOL’s convertible notes. The new TopCo entity is expected to begin trading in the second half of 2025 (subject to approval and ATO rulings). A free float-adjusted market cap of ~A$12.6bn will also likely see it enter the ASX50.

2025 investor day

Judo Capital Holdings
3:27pm
June 3, 2025
JDO’s investor day included briefings from senior management and a panel discussion with clients of the bank. The briefing gave us increased confidence in the strength of JDO’s management, business model, and earnings growth outlook. ACCUMULATE with potential TSR at current prices of c.19%. Target price $1.75/sh.

International Spotlight

Vertex Pharmaceuticals Inc
3:27pm
June 3, 2025
Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious and life-threatening diseases. Founded in 1989 in Cambridge, Massachusetts, the corporate headquarters is now located in Boston’s Innovation District, with the international headquarters in London, United Kingdom. Currently, Vertex has approximately 3,500 employees in the United States, Europe, Canada, Australia and Latin America with nearly two-thirds of staff dedicated to research and development. Vertex is recognised as one of the industry’s top places to work by Science Magazine, The Boston Globe, Boston Business Journal and the San Diego Business Journal. Vertex’s research and medicines have also received esteemed recognitions, including the Robert J. Beall Therapeutics Development Award, the French Prix Galien and the British Pharmacological Society awards.

News & Insights

Michael Knox, Chief Economist looks at what might have happened in January 2026 if the cuts in corporate tax rates in Trumps first term were not renewed and extended in the One Big Beautiful Bill

In recent weeks, a number of media commentators have criticized Donald Trump's " One big Beautiful Bill " on the basis of a statement by the Congressional Budget Office that under existing legislation the bill adds $US 3.4 trillion to the US Budget deficit. They tend not to mention that this is because the existing law assumes that all the tax cuts made in 2017 by the first Trump Administration expire at the end of this year.

Let’s us look at what might have happened in January 2026 if the cuts in US corporate tax rates in Trumps first term were not renewed and extended in the One Big Beautiful Bill.

Back in 2016 before the first Trump administration came to office in his first term, the US corporate tax rate was then 35%. In 2017 the Tax Cut and Jobs Act reduced the corporate tax rate to 21%. Because this bill was passed as a "Reconciliation Bill “, This meant it required only a simple majority of Senate votes to pass. This tax rate of 21% was due to expire in January 2026.

The One Big Beautiful Bill has made the expiring tax cuts permanent; this bill was signed into law on 4 July 2025. Now of course the same legislation also made a large number of individual tax cuts in the original 2017 bill permanent.

What would have happened if the bill had not passed. Let us construct what economists call a "Counterfactual"

Let’s just restrict ourselves to the case of what have happened in 2026 if the US corporate tax had risen to the prior rate of 35%.

This is an increase in the corporate tax rate of 14%. This increase would generate a sudden fall in US corporate after-tax earnings in January 2026 of 14%. What effect would that have on the level of the S&P 500?

The Price /Earnings Ratio of the S&P500 in July 2025 was 26.1.

Still the ten-year average Price/ Earnings Ratio for the S&P500 is only 18.99. Let’s say 19 times.

Should earnings per share have suddenly fallen by 14%, then the S&P 500 might have fallen by 14% multiplied by the short-term Price/ Earnings ratio.

This means a likely fall in the S&P500 of 37%.

As the market recovered to long term Price Earnings ratio of 19 this fall might then have ben be reduced to 27%.

Put simply, had the One Big, beautiful Bill not been passed, then in 2026 the US stock market might suddenly have fallen by 37% before then recovering to a fall of 27% .

The devastating effect on the US and indeed World economy might plausibly have caused a major recession.

On 9 June Kevin Hassert the Director of the National Economic Council said in a CBS interview with Margaret Brennan that if the bill did not pass US GDP would fall by 4% and 6-7 million Americans would lose their jobs.

The Passage of the One Big Beautiful Bill on 4 July thus avoided One Big Ugly Disaster.

Read more
On 7 July the AFR published a list of 37 Economists who had answered a poll on when the RBA would next cut rates. 32 of them thought that the RBA would cut on 8 July. Only 5 of them did not believe the RBA would cut, Michael Knox being one of them.

On 7 July the AFR published a list of 37 Economists who had answered a poll on when the RBA would next cut rates. 32 of them thought that the RBA would cut on 8 July. Only 5 of them did not believe the RBA would cut on 8 July. I was one of them. The RBA did not cut.

So today I will talk about how I came to that decision. First, lets look at our model of official interest rates. Back in January 2015 I went to a presentation in San Franciso by Stan Fishcer . Stan was a celebrated economist who at that time was Ben Bernanke's deputy at the Federal Reserve. Stan gave a talk about how the Fed thought about interest rates.

Stan presented a model of R*. This is the real short rate of the Fed Funds Rate at which monetary policy is at equilibrium. Unemployment was shown as a most important variable. So was inflationary expectations.

This then logically lead to a model where the nominal level of the Fed funds rate was driven by Inflation, Inflationary expectations and unemployment. Unemployment was important because of its effect on future inflation. The lower the level of unemployment the higher the level of future inflation and the higher the level of the Fed funds rate. I tried the model and it worked. It worked not just for the Fed funds rate. It also worked in Australia for Australian cash rate.

Recently though I have found that while the model has continued to work to work for the Fed funds rate It has been not quite as good in modelling that Australian Cash Rate. I found the answer to this in a model of Australian inflation published by the RBA. The model showed Australian Inflation was not just caused by low unemployment, It was also caused by high import price rises. Import price inflation was more important in Australia because imports were a higher level of Australian GDP than was the case in the US.

This was important in Australia than in the US because Australian import price inflation was close to zero for the 2 years up to the end of 2024. Import prices rose sharply in the first quarter of 2025. What would happen in the second quarter of 2025 and how would it effect inflation I could not tell. The only thing I could do is wait for the Q2 inflation numbers to come out for Australia.

I thought that for this reason and other reasons the RBA would also wait for the Q2 inflation numbers to come out. There were other reasons as well. The Quarterly CPI was a more reliable measure of the CPI and was a better measure of services inflation than the monthly CPI. The result was that RBA did not move and voiced a preference for quarterly measure of inflation over monthly version.

Lets look again at R* or the real level of the Cash rate for Australia .When we look at the average real Cash rate since January 2000 we find an average number of 0.85%. At an inflation target of 2.5 % this suggests this suggest an equilibrium Cash rate of 3.35%

Model of the Australian Cash Rate.
Model of the Australian Cash Rate


What will happen next? We think that the after the RBA meeting of 11 and 12 August the RBA will cut the Cash rate to 3.6%

We think that after the RBA meeting of 8 and 9 December the RBA will cut the Cash rate to 3.35%

Unless Quarterly inflation falls below 2.5% , the Cash rate will remain at 3.35% .

Read more
Investment Watch is a quarterly publication for insights in equity and economic strategy. Recent months have been marked by sharp swings in market sentiment, driven by shifting global trade dynamics, geopolitical tensions, and policy uncertainty.

Investment Watch is a quarterly publication produced by Morgans that delves into key insights for equity and economic strategy.

This publication covers

Economics - 'The challenge of Australian productivity' and 'Iran, from the Suez blockade to the 12 day war'
Asset Allocation
- 'Prioritise portfolio resilience amidst the prevailing uncertainty'
Equity Strategy
- 'Rethinking sector preferences and portfolio balance'
Fixed Interest
- 'Market volatility analysis: Low beta investment opportunities'
Banks
- 'Outperformance driving the broader market index'
Industrials
- 'New opportunities will arise'
Resources and Energy
- 'Getting paid to wait in the majors'
Technology
- 'Buy the dips'
Consumer discretionary
- 'Support remains in place'
Telco
- 'A cautious eye on competitive intensity'
Travel
- 'Demand trends still solid'
Property
- 'An improving Cycle'

Recent months have been marked by sharp swings in market sentiment, driven by shifting global trade dynamics, geopolitical tensions, and policy uncertainty. The rapid pace of US policy announcements, coupled with reversals, has made it difficult for investors to form strong convictions or accurately assess the impact on growth and earnings. While trade tariffs are still a concern, recent progress in US bilateral negotiations and signs of greater policy stability have reduced immediate headline risks.

We expect that more stable policies, potential tax cuts, and continued innovation - particularly in AI - will support a gradual pickup in investment activity. In this environment, we recommend prioritising portfolio resilience. This means maintaining diversification, focusing on quality, and being prepared to adjust exposures as new risks or opportunities emerge. This quarter, we update our outlook for interest rates and also explore the implications of the conflict in the Middle East on portfolios. As usual, we provide an outlook for the key sectors of the Australian market and where we see the best tactical opportunities.


Morgans clients receive exclusive insights such as access to our latest Investment Watch publication. Contact us today to begin your journey with Morgans.

      
Contact us
      
      
Find an adviser
      
Read more